SCHEMBL4590548

SCHEMBL4590548

NCC12CCCN1CCC2

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.38
RAD52 P43351 1/20 0.38
KMT2A Q03164 1/20 0.38
CHRNA7 P36544 1/20 0.33
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16757065 0.95 KMT2A (0.36) GAARAD52KMT2ACHRNA7KCNH2
SCHEMBL25165704 0.92 KMT2A (0.37) GAARAD52KMT2AKCNH2
SCHEMBL8265735 0.92 KMT2A (0.37) GAARAD52KMT2AKCNH2
SCHEMBL30699749 0.92 GAA (0.37) GAARAD52KMT2A
SCHEMBL3930544 0.90 KMT2A (0.36) GAARAD52KMT2AKCNH2
SCHEMBL553125 0.90 KMT2A (0.36) GAARAD52KMT2AKCNH2
SCHEMBL31441143 0.90 KMT2A (0.36) GAARAD52KMT2AKCNH2
SCHEMBL470816 0.90 KMT2A (0.36) GAARAD52KMT2A
Hydrochloric Acid SCHEMBL1828960 0.87 OPRM1 (0.35) GAARAD52KMT2AKCNH2
SCHEMBL18796116 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0345712-B1 PYRROLIZINE DERIVATE AND ITS MANUFACTURE SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1992-10-07 EP claimed
EP-0345711-A2 Process for the preparation of pyrrolizine derivatives SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-12-13 EP claimed
EP-0345712-A1 Pyrrolizine derivate and its manufacture SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-12-13 EP claimed
JP-61229893-A None JP disclosed
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
EP-4387963-B1 PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 REDX PHARMA LTD (GB) 2025-12-24 EP disclosed
US-20250154156-A1 QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR SHENZHEN FORWARD PHARMACEUTICALS CO., LIMITED (CN) 2025-05-15 US disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025077825-A1 METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS FAUNA BIO INCORPORATED (US) 2025-04-17 WO disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
WO-2024015262-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2024-01-18 WO disclosed
US-4985569-A Pyrrolizine derivative and its manufacture SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1991-01-15 US disclosed
US-4985569-A Pyrrolizine derivative and its manufacture SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1991-01-15 US disclosed
US-4897495-A Process for the preparation of pyrrolizine derivatives SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1990-01-30 US disclosed
EP-0345712-A1 Pyrrolizine derivate and its manufacture SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-12-13 EP disclosed
EP-0345711-A2 Process for the preparation of pyrrolizine derivatives SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-12-13 EP disclosed
US-4617401-A ANTISPASMODIC AGENTS, VASODILATORS SUNTORY LTD. (JP) 1986-10-14 US disclosed
JP-S61229893-A NOVEL ORGANOPLATINUM COMPLEX, PRODUCTION THEREOF, AND ANTITUMOR AGENT CONTAINING SAID COMPLEX AS ACTIVE COMPONENT SANWA KAGAKU KENKYUSHO:KK 1986-10-14 JP disclosed
EP-0039903-B1 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF SUNTORY KABUSHIKI KAISHA (JP) 1986-04-09 EP disclosed
EP-0039903-A2 8-Substituted pyrrolizidines and quaternary ammonium salts thereof SUNTORY KABUSHIKI KAISHA (JP) 1981-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS GAA 2022/4885RAD52 3080/4885KMT2A 1823/4885
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, GMPS, PRKG1 GAA 163/4885RAD52 3246/4885KMT2A 4776/4885
US-20250154156-A1 QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR KRAS, NRAS, HRAS GAA 1002/4885RAD52 2286/4885KMT2A 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.